Patents Assigned to Idenix Pharmaceuticals, LLC
-
Publication number: 20190192548Abstract: The present invention relates to methods of treating or preventing a viral infection using Compounds of Formula (I); or a pharmaceutically acceptable salt thereof, wherein A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates to compositions comprising a Compound of Formula (I).Type: ApplicationFiled: June 20, 2017Publication date: June 27, 2019Applicants: MERCK SHARP & DOHME CORP., IDENIX PHARMACEUTICALS LLCInventors: Stephane BOGEN, David DUKHAN, Cyril B. DOUSSON, Christophe Claude PARSY
-
Publication number: 20190183912Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: August 22, 2017Publication date: June 20, 2019Applicants: Merck Sharp & Dohme Corp., IDENIX PHARMACEUTICALS LLCInventors: Daniel Da Costa, Cyril B. Dousson, David Dukhan, Jean-Laurent Paparin, Houcine Rahali, Izzat Raheem
-
Publication number: 20190185508Abstract: The present invention is directed to deuterated 4?-substituted nucleoside derivatives of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC.Type: ApplicationFiled: December 6, 2018Publication date: June 20, 2019Applicants: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLCInventors: Francois-Rene Alexandre, Izzat Raheem
-
Publication number: 20190177326Abstract: The present invention is directed carbocyclic nucleoside reverse transcriptase inhibitors compounds of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC.Type: ApplicationFiled: December 6, 2018Publication date: June 13, 2019Applicants: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLCInventors: Francois-Rene Alexandre, Rachid Rahali, Izzat Raheem, Christophe Parsy
-
Patent number: 10251903Abstract: The present invention is directed to a process for making Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).Type: GrantFiled: October 20, 2015Date of Patent: April 9, 2019Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLCInventors: Bryon L. Simmons, Kevin R. Campos, Artis Klapars, Alistair J. Stewart, Benjamin A. Mayes, Peter E. Maligres, Alan Hyde, Steven Mark Silverman, Yong-Li Zhong, Adel M. Moussa, Kenneth Baker, Kara Van Valkenburg
-
Patent number: 10238680Abstract: Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.Type: GrantFiled: November 30, 2015Date of Patent: March 26, 2019Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIERInventors: Benjamin Alexander Mayes, Adel M. Moussa, Cyril B. Dousson, Gilles Gosselin, Claire Pierra, David Dukhan
-
Patent number: 10231986Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, R1 and R2 are as described herein.Type: GrantFiled: September 25, 2015Date of Patent: March 19, 2019Assignee: IDENIX PHARMACEUTICALS LLCInventors: David Dukhan, Christophe Claude Parsy, Gilles Gosselin, Jean-François Griffon, Guillaume Brandt, Cyril B. Dousson, Adel M. Moussa, Benjamin Alexander Mayes, Alistar James Stewart
-
Patent number: 10202411Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.Type: GrantFiled: April 16, 2015Date of Patent: February 12, 2019Assignee: IDENIX PHARMACEUTICALS LLCInventors: David Dukhan, Cyril B. Dousson, Gilles Gosselin, Jean-Laurent Paparin, Guillaume Brandt, Rachid Rahali, Aurelien Salanson, François-René Alexandre
-
Publication number: 20180362562Abstract: Compounds of Formula I and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: December 5, 2016Publication date: December 20, 2018Applicants: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLCInventors: Izzat Tiedje Raheem, Timothy J. Hartingh, John Schreier, Jean-Laurent Paparin
-
Patent number: 10030044Abstract: Provided herein are compounds, compositions and methods for the treatment of liver cancer such as hepatocellular carcinoma, cholangiocarcinoma, or biliary tract cancer. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-cancer agents. In certain embodiments, the compounds are nucleoside analogs of Formula I: (I); or a pharmaceutically acceptable salt thereof, wherein Base, Z1, Z2, Z3, Z4, V, W, X, Ar, R1 and R2 are as described herein.Type: GrantFiled: November 25, 2014Date of Patent: July 24, 2018Assignee: IDENIX PHARMACEUTICALS LLCInventors: Cyril B. Dousson, David Dukhan, Christophe Claude Parsy
-
Publication number: 20180179208Abstract: Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS.Type: ApplicationFiled: December 20, 2017Publication date: June 28, 2018Applicants: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLCInventors: Jean-Laurent Paparin, Izzat Raheem, Houcine Rahali, Daniel Da Costa, David Dukhan
-
Patent number: 10005779Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 1?,4?-thio nucleoside compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula 3001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof; wherein Base, RA, RB, W, X, Y, and Z are as described herein.Type: GrantFiled: June 4, 2014Date of Patent: June 26, 2018Assignee: IDENIX PHARMACEUTICALS LLCInventors: David Dukhan, Gilles Gosselin, Cyril B. Dousson
-
Publication number: 20180162898Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4?-OR nucleosides of Formula I: or a pharmaceutically acceptable salt thereof, wherein Base, PD, R, Z1, Z2, Z3, and Z4 are as defined herein.Type: ApplicationFiled: December 17, 2014Publication date: June 14, 2018Applicant: IDENIX PHARMACEUTICALS LLCInventors: David Dukhan, Cyril B. Dousson, Adel M. Moussa, Benjamin Alexander Mayes, James Alistair Stewart
-
Publication number: 20180155385Abstract: The present invention relates to novel nucleoside derivatives, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.Type: ApplicationFiled: May 23, 2016Publication date: June 7, 2018Applicant: IDENIX PHARMACEUTICALS LLCInventors: Cyril B. DOUSSON, David DUKHAN, Christophe Claude PARSY
-
Patent number: 9968628Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.Type: GrantFiled: November 13, 2012Date of Patent: May 15, 2018Assignees: Idenix Pharmaceuticals LLC, Universita Degli Studi Di CagliariInventors: Jean-Pierre Sommadossi, Paolo LaColla
-
Publication number: 20170246198Abstract: The present invention is directed to a process for making Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).Type: ApplicationFiled: October 20, 2015Publication date: August 31, 2017Applicants: IDENIX Pharmaceuticals LLC, Merck Sharp & Dohme Corp.Inventors: Bryon L. SIMMONS, Kevin R. CAMPOS, Artis KLAPARS, Alistair J. STEWART, Benjamin A. MAYES, Peter E. MALIGRES, Alan HYDE, Steven Mark SILVERMAN, Yong-Li ZHONG, Adel M. MOUSSA, Kenneth BAKER, Kara van VALKENBURG
-
Publication number: 20170198005Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-dichloro or 2?-fluoro-2?-chloro nucleoside analogue compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula (I): or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof; wherein each of RA and RB is independently Cl or F, wherein at least one of RA and RB is Cl; and Base, PD and Z are as described herein.Type: ApplicationFiled: November 26, 2014Publication date: July 13, 2017Applicant: IDENIX PHARMACEUTICALS LLCInventors: Jean-Laurent Paparin, Eric Badaroux, Claire Pierra, Cyril B. Dousson
-
Publication number: 20170135990Abstract: Provided herein are spray-dried particles comprising a 5,5-fused heteroarylene hepatitis C virus inhibitor compound and methods of their preparation. Also provided herein are pharmaceutical compositions comprising a 5,5-fused heteroarylene hepatitis C virus inhibitor compound, method of their preparation, and their use for treating or preventing hepatitis C virus infection.Type: ApplicationFiled: March 4, 2015Publication date: May 18, 2017Applicant: Idenix Pharmaceuticals LLCInventors: Adel M. Moussa, Benjamin Alexander Mayes, Sindhura Ganga
-
Publication number: 20170101431Abstract: Provided herein are compounds, compositions, and methods for the treatment of cancer, including leukemia. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-cancer agents.Type: ApplicationFiled: May 27, 2015Publication date: April 13, 2017Applicant: IDENIX PHARMACEUTICALS LLCInventors: Cyril Dousson, David Dukhan, Christophe Claude Parsy, Francois-Rene Alexandre, Rachid Rahali, Jean-Laurent Paparin
-
Publication number: 20170066779Abstract: Provided herein are crystalline and salt forms of methyl N-{(1R)-2-[(2S)-2-{5-[4-(6-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl} pyrrolidin-2-yl]-3H-benzimidazol-5-yl}thieno[3,2-b]thiophen-3-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl} carbamate, a Flaviviridae, including hepatitis C, virus inhibitor, pharmaceutical compositions comprising the compound, and processes of preparation thereof. Also provided are methods of its use for the treatment of a Flaviviridae, including HCV, infection in a subject in need thereof.Type: ApplicationFiled: March 4, 2015Publication date: March 9, 2017Applicant: IDENIX Pharmaceuticals LLCInventors: Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart